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Abstract
Purpose In peptide-receptor radionuclide therapy (PRRT),
the maximum activity dose that can safely be administered
is limited by high renal uptake and retention of radio-
labelled peptides. The kidney radiation dose can be reduced
by coinfusion of agents that competitively inhibit the
reabsorption of radiolabelled peptides, such as positively
charged amino acids, Gelofusine, or trypsinised albumin.
The aim of this study was to identify more specific and
potent inhibitors of the kidney reabsorption of radiolabelled
peptides, based on albumin.
Methods Albumin was fragmented using cyanogen bro-
mide and six albumin-derived peptides with different
numbers of electric charges were selected and synthesised.
The effect of albumin fragments (FRALB-C) and selected
albumin-derived peptides on the internalisation of
111In-
albumin,
111In-minigastrin,
111In-exendin and
111In-octreo-
tide by megalin-expressing cells was assessed. In rats, the
effect of Gelofusine and albumin-derived peptides on the
renal uptake and biodistribution of
111In-minigastrin,
111In-
exendin and
111In-octreotide was determined.
Results FRALB-C significantly reduced the uptake of all
radiolabelled peptides in vitro. The albumin-derived pep-
tides showed different potencies in reducing the uptake of
111In-albumin,
111In-exendin and
111In-minigastrin in vitro.
The most efficient albumin-derived peptide (peptide #6),
was selected for in vivo testing. In rats, 5 mg of peptide #6
very efficiently inhibited the renal uptake of
111In-mini-
gastrin, by 88%. Uptake of
111In-exendin and
111In-
octreotide was reduced by 26 and 33%, respectively.
Conclusions The albumin-derived peptide #6 efficiently
inhibited the renal reabsorption of
111In-minigastrin,
111In-
exendin and
111In-octreotide and is a promising candidate
for kidney protection in PRRT.
Keywords Kidney.Peptide-receptorradionuclidetherapy.
Octreotide.Minigastrin.Exendin.Albumin
Introduction
Excretion of radiolabelled hydrophilic peptides and small
proteins occurs largely via the kidneys. In peptide-receptor
radionuclide therapy (PRRT), rapid clearance of the radio-
labelled peptides from the blood and low retention in the
kidneys are important to minimise the radiation dose to
normal tissues. However, as outlined in more detail
previously [1], a part of the filtered load of these small
proteins and peptides is reabsorbed from the ultrafiltrate in
the proximal tubules and retained there, exposing the
kidneys to a relatively high radiation dose. Indeed, acute
and chronic kidney damage have been described in patients
receiving PRRT and in animal models [2–5] and kidney
toxicity is currently dose-limiting in PRRT [3, 4, 6].
Reduction of the renal radiation dose by reducing the renal
retention of radiolabelled peptides facilitates the adminis-
tration of higher activity doses in PRRT, which is expected
to increase its therapeutic effect.
A possible approach to reducing the renal reabsorption
of radiolabelled peptides is to interfere with endocytic
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involved in the tubular reabsorption of peptides have not
yet been characterised completely, but for various peptides,
involvement of megalin and cubilin has been shown [7–10].
Cubilin is a large extracellular receptor that depends on
other receptors such as megalin for its internalisation.
Megalin is a multiligand receptor belonging to the LDL
receptor family. The receptor contains four large cysteine-
rich ligand binding domains and is a high-capacity transport
system with varying affinity for the reabsorption of a large
series of structurally non-related compounds, such as
albumin, vitamin D binding protein, β2-microglobulin,
aprotinin, Ca
2+, etc. [7, 11, 12]. Charges may play an
important role in the binding of ligands to megalin [12, 13]
or to other renal receptors. Gotthardt et al. found a positive
correlation between the renal retention and the total number
of charged amino acid residues of radiolabelled peptides,
and suggested a causal relationship [14]. It has been shown
that some ligands bind to megalin via their cationic sites
and that co-administration of cationic compounds can
inhibit the renal reabsorption of these ligands [8, 15].
Indeed, in patients undergoing PRRT with radiolabelled
somatostatin analogues as well as in various animal models,
the renal uptake of different radiolabelled peptides and
antibody fragments can effectively be reduced by co-
administration of basic amino acids [16–19]. However,
these compounds can cause side-effects at high doses, such
as nausea, hyperkalemia, arrhythmias and even nephrotox-
icity [15, 18, 20]. Succinylated gelatin (Gelofusine, Gelo), a
plasma expander that consists of a mixture of collagen-
derived peptides, has also been shown to efficiently reduce
the renal reabsorption of various radiolabelled peptides in
animals, and of
111In-octreotide in humans [1, 21–23].
Nevertheless, more efficient inhibitors are needed since
none of these substances completely inhibits the reabsorp-
tion of radiolabelled peptides.
Albumin, the most abundant plasma protein, is a natural
ligand of megalin and cubilin. Due to albumin’s size and
charge (67 kDa, predominantly anionic at physiological
pH), only a small fraction of circulating albumin is filtered
in the glomeruli [13, 24, 25]. This small fraction is
subsequently reabsorbed by megalin/cubilin-mediated en-
docytosis. Previously, we showed that peptide fragments
obtained by trypsinisation of bovine serum albumin (BSA)
reach higher concentrations in the proximal tubules than
intact albumin and are efficient inhibitors of the renal
reabsorption of
111In-octreotide,
111In-exendin and
111In-
minigastrin in rats [1]. However, trypsin cleaves peptides at
the carboxyl terminus of arginine and lysine residues [26].
Since BSA contains 78 arginine and lysine residues, its
trypsinisation yields a complex mixture of many different
albumin fragments. We hypothesised that some of these
may not actually contribute to the blocking of the renal
reuptake of radiolabelled peptides, but might cause side
effects. Better defined albumin fragments may be obtained
by digestion of albumin by cyanogen bromide (CNBr) in
formic acid. CNBr cleaves peptides at the carboxyl
terminus of methionine residues and formic acid cleaves
peptides at aspartic acid–proline bonds [27]. BSA has four
methionine residues and two aspartic acid–proline bonds.
Thus, digestion of BSA by CNBr in formic acid yields a
maximum of 28 possible fragments.
Since megalin binds various structurally different peptides
and proteins, we hypothesised that different fragments of
albumin may bind to megalin and be potential candidates for
inhibiting the renal reuptake of radiolabelled peptides. In
addition to the mixture of CNBr-digested albumin fragments
(FRALB-C), a set of albumin-derived peptides was selected.
The selection of these peptides was based on the distribution
of charged amino acid residues in BSA. We aimed to identify
albumin fragments that potently inhibit the renal reabsorption
of radiolabelled peptides, in order to maximise the inhibitory
effect and to minimise potential side effects.
In this study, the effect of FRALB-C and a series of
synthesised albumin-derived peptides on the renal uptake of
[
111In-DTPA-d-Phe
1]-octreotide (
111In-octreotide), [Lys
40(a-
minohexanoic acid-DTPA-
111In)NH2]-exendin-3 (
111In-exen-
din) and [
111In-DOTA-Glu
1]-minigastrin (
111In-minigastrin)
was analyzed, both in vitro and in rats.
Materials and methods
Fragmentation of albumin
Intact BSA (2.26µmol (150 mg), Sigma) was added to
4.5 ml of 70% v/v formic acid with dithiothreitol (6.7 mM)
and heated for 2 min at 100°C. Subsequently, 1.13 mmol of
CNBr (Sigma) was added and the mixture was incubated
for 24 h at room temperature in the dark, followed by 5 min
of incubation at 50°C. The acid was neutralised by adding
9 ml of 4-ethylmorpholine (Sigma), after which the mixture
was dialyzed against phosphate buffered saline (PBS). The
fragmented albumin was analyzed by fast protein liquid
chromatography (FPLC) and sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). The
protein concentration in the FRALB-C mixture was
determined with the Bio-Rad Protein Assay using intact
BSA as a reference.
Selection and synthesis of albumin fragments
Six parts of the BSA amino acid sequence were selected for
peptide synthesis. The selection was based on the distribu-
tion of charged amino acid residues in these sequences and
their net charge at physiological pH. Five peptides contain-
Eur J Nucl Med Mol Imaging (2010) 37:226–234 227ing different combinations of positive and negative charges
were selected and synthesised, each composed of 16 amino
acid residues. An uncharged peptide was synthesised as
well, but this was not studied since it could not be dissolved
in water. A sixth peptide was synthesised, which was the
smallest possible fragment formed after CNBr digestion of
BSA, consisting of the 36 C-terminal amino acid residues.
The characteristics of the synthesised peptides are summar-
ised in Table 1. Peptides were synthesised by standard
solid-phase F-moc chemistry and purified by high-
performance liquid chromatography (HPLC) at Peptide
Specialty Laboratories GmbH (Heidelberg, Germany) and
at Peptide 2.0 (Chantilly, VA, USA).
Other compounds used to reduce renal reabsorption
Gelofusine (Gelo, Braun) is a solution of succinylated
gelatin fragments (40 g/l). The molecular mass of these
fragments in Gelo averages 30 kDa. Intact BSA was
dissolved in PBS at a concentration of 100 g/l. Lysine
solution was prepared as a 160 g/l solution in PBS.
Radiolabeling
[DTPA-d-Phe
1]-octreotide (Octreoscan, Covidien) was la-
belled with
111In by adding 37 MBq of
111InCl3 (Covidien)
to 1µg of Octreoscan and incubating for 30 min at room
temperature. [Lys
40(Ahx-DTPA)NH2]-exendin-3 (exendin,
Peptide Specialty Laboratories GmbH, Heidelberg, Germany)
was synthesised using standard F-moc chemistry. The
peptide was labelled with
111InCl3 in a 0.1 M 2-(N-
morpholino)ethanesulfonic acid (MES) buffer, pH 5.5. A
mixture of 19 MBq of
111In and 1µg of exendin was
incubated for 30 min at room temperature. [DOTA-Glu
1]-
minigastrin (minigastrin, Peptide Specialty Laboratories) was
synthesised using standard F-moc chemistry. Minigastrinwas
labelled with
111InCl3 in a 0.25 M ammonium acetate buffer,
pH 5.5.
111InCl3 (22.2 MBq) was added to 1µg of minigastrin
and the mixture was incubated at 95°C for 25 min.
BSA was conjugated with DTPA as described by
Hnatowich et al. [28] and labelled with
111In by adding
11 MBq of
111InCl3 to 1µg of DTPA-BSA in a 0.25 M
ammonium acetate buffer, pH 5.5 (100µl) and incubating
for 20 min at room temperature. Radiochemical purity and
labeling efficiency of the labelled peptides and proteins
were determined by silica gel instant thin layer chromatog-
raphy and reverse phase HPLC.
In vitro studies
Rat yolk sac epithelial (BN16) cells, expressing megalin and
cubilin [29, 30] were kindly provided by Prof. P.J. Verroust.
Cells were cultured at 37°C in BN16 medium, consisting of
Dulbecco’s modified Eagle’s medium plus 4.5 g/l glucose
(Invitrogen) with 10% fetal calf serum, 100 U/ml penicillin
and 100 μg/ml streptomycin (Invitrogen).
The potency of FRALB-C to inhibit the interaction of
the radiolabelled peptides with BN16 cells was determined
in vitro in triplicate. The cells were seeded into 6-well
plates at 3 × 10
5 cells/well and cultured until confluent. The
cells were washed with PBS and incubated for 1 h with
serum-free BN16 medium. The cells were washed again
with PBS, and 2 ml of Ringer’s solution (Braun) with
10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) buffer, pH 7.4 was added. Subsequently, 100µl of
the inhibitor was added: either PBS, Gelo or 100µg of
FRALB-C. Directly after addition of the inhibitor, 80 kBq
(50µl) of
111In-albumin,
111In-octreotide,
111In-exendin or
111In-minigastrin was added. After 1 h of incubation at 37°C,
cells were rinsed with Ringer’s solution and harvested using
cotton swabs. Radioactivity was measured in a shielded well-
type gamma counter (Wizard,Wallac). To study the inhibitory
potency of the albumin-derived peptides, the same procedure
was used. Increasing doses of the six peptides (10, 30 and
Table 1 Characterisation of albumin-derived peptides*
# Amino acid sequence Number of 
charged AA 
residues at pH 7
Net 
charge 
at pH 7
Iso- 
electric 
point 
Molecular 
mass 
(Da)
Location 
in BSA 
(AA 
numbers)
+ - total
1 5 3 8 +2 10.4 2103 129-144
2 4 0 4 +4 12.3 1809 191-206
3 4 4 8 0 4.7 1840 279-294
4 0 4 4 -4 2.7 1714 295-310
5 2 4 6 -2 4.2 1825 489-504
6 3 6 9 -3 4.5 3792 548-583
*Characteristics of the albumin-derived peptides that were synthesised and studied in our in vitro assay. AA = amino acid. Positively and
negatively charged amino acid residues are printed in red and blue, respectively.
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intact albumin (10 mg) and Gelo (5 mg) to reduce the binding
of
111In-albumin,
111In-exendin and
111In-minigastrin. Inter-
nalisation of these radiolabelled compounds by BN16 cells
was studied using essentially the same assay. Cells were
incubated with
111In-albumin,
111In-exendin or
111In-mini-
gastrin for 1 h at 37°C or 0°C. Internalised activity and cell-
surface bound activity was determined by incubating the
cells for 10 min in 1 ml 0.1 M acetic acid, 154 mM NaCl,
pH 2.8 at 0°C. The activity in the supernatant (cell-surface
bound) and the activity in the cells (internalised) was
determined.
Animal studies
Groups of five male Wistar rats (200–220 g) were used in all
experiments. The potency of FRALB-C to inhibit the renal
reabsorption of
111In-octreotide was compared with the
reference agents PBS, lysine and Gelo. The animals were
injected i.v. with 0.5 ml of the inhibitor (either PBS, lysine
(80 mg), Gelo (20 mg) or FRALB-C (1 mg, 5 mg or 20 mg))
via the tail vein. One minute later,
111In-octreotide was
injected i.v. (2 MBq/rat).
The animals were killed 20 h after injection and a blood
sample was drawn and organs were dissected. The kidneys,
adrenals, spleen and stomach, as well as samples of muscle,
lung, pancreas, liver and duodenum were harvested. The
tissues were weighed and counted in a shielded well-type
gamma counter together with the injection standards.
Radioactivity concentration was expressed as percentage
of the injected dose per gram tissue (% ID/g).
The albumin-derived peptide which most potently
reduced the binding of
111In-minigastrin and
111In-exendin
in the cell binding assay, peptide #6, was studied in rats
according to the same procedure. The effect of peptide #6
(0.2 mg, 1 mg or 5 mg per rat) on the uptake of
111In-
minigastrin,
111In-exendin and
111In-octreotide was studied
and compared to PBS and Gelo (20 mg per rat) as negative
and positive control, respectively.
Statistical analysis
Data are presented as mean % reduction ± standard deviation.
The analysis of differences in cell binding and kidney uptake
was performed using Student’s t-test. Biodistribution data
in other organs were analyzed by one-way ANOVA.
The significance level was set at 0.05.
Results
Radiolabelling
Radiochemical purity and labelling efficiency of all com-
pounds were higher than 95%.
In vitro studies
The internalisation assay showed that at 37°C, >90% of cell-
associated
111In-albumin and
111In-minigastrin and >75% of
111In-exendin was internalised (data not shown). This
indicates that these radiolabelled compounds were rapidly
internalised by the BN16 cells.
As summarised in Fig. 1, FRALB-C significantly
reduced the uptake of all radiolabelled peptides in BN16
cells. A dose of 100µg of FRALB-C per incubation
reduced the uptake of
111In-albumin by 75%±5.7% (p<
0.001, Fig. 1a). The uptake of
111In-minigastrin, -exendin
and -octreotide was reduced by 95%±6.3% (p<0.001),
67%±6.9% (p<0.001) and 39%±7.4% (p<0.01), respec-
tively (Fig. 1b–d). The lower doses of 30µg and 10µg
FRALB-C were less effective (data not shown). Gelofusine
(4 mg) significantly reduced the uptake of all radiolabelled
peptides as well.
The effects of 100µg of the six albumin-derived peptides
on the uptake of
111In-albumin, -minigastrin and -exendin
in BN16 cells are summarised in Fig. 2. The uptake of
111In-albumin (Fig. 2a) was inhibited significantly (all p<
Fig. 1 Inhibition of the uptake of
111In-albumin (a),
111In-minigastrin (b),
111In-exendin (c)a n d
111In-octreotide (d) in BN16 cells by Gelo (4 mg) or
FRALB-C (100µg). Results are presented as mean % bound activity; error bars indicate standard error of the mean (SEM). *P<0.05; **P<0.005
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9.1%), peptide #5 (37%±11%) and most potently by
peptide #6 (75%±9.1%), as well as by intact albumin
(91%±9.1%) and Gelo (65%±9.0%).
As depicted in Fig. 2b, the uptake of
111In-minigastrin
was reduced significantly by peptide #3 (60%±6.0%, p=
0.002), peptide #4 (76%±4.5%, p=0.0002), peptide #5
(37%±5.7%, p=0.005) and peptide #6 (96%±4.3%, p<
0.0001). Albumin and Gelo also significantly reduced the
uptake, by 90%±4.5% and by 98%±4.3% respectively (both
p<0.0002).
T h eu p t a k eo f
111In-exendin by BN16 cells (Fig. 2c)
was reduced significantly by peptide #3 (42%±6.2%, p=
0.001), peptide #5 (18%±6.4%, p=0.03) and most
potently by peptide #6 (94%±6.1%, p<0.0001), as well
as by albumin and Gelo (94%±6.2% and 91%±6.1%
respectively, both p<0.0001).
The lower doses of 30µg and 10µg of the albumin-
derived peptides were less effective in inhibiting the uptake
of these
111In-labelled peptides (data not shown).
Animal studies
The effect of FRALB-C on the renal retention of
111In-
octreotide in rats is summarised in Fig. 3. FRALB-C (1 mg)
reduced the renal uptake of
111In-octreotide by 24%±12%
(p=0.02). Higher doses of FRALB-C (up to 20 mg) did not
increase this effect. Lysine (80 mg) and Gelo (20 mg)
reduced the uptake by 36%±11% and 27%±9.7%, respec-
tively (both p<0.003). FRALB-C had no significant effect
on the uptake of
111In-octreotide in the pancreas, adrenals
or other organs.
Figure 4 summarises the effect of peptide #6 on the
renal retention of
111In-minigastrin,
111In-exendin and
111In-octreotide in rats. Peptide #6 had a pronounced
effect on the renal uptake of
111In-minigastrin: 5 mg of
peptide #6 reduced the uptake by 88%±9.0% (p<0.0001).
Gelo reduced the uptake by 77%±8.9% (p<0.0001). The
renal uptake of
111In-exendin was reduced by 26%±3.4%
by peptide #6, whereas Gelo reduced the uptake by 16%±
3.1% (both p<0.0001). The highest dose of peptide #6
reduced the uptake of
111In-octreotide by 33%±13% (p=
0.004), comparable to the effect of 20 mg of Gelo (28%±
9.9%, p= 0 . 0 0 2 ) .T h el o w e rd o s e so f1m ga n d0 . 2m go f
peptide #6 were less effective in inhibiting the renal
uptake of the
111In-labelled peptides.
Peptide #6 significantly reduced the uptake of
111In-
octreotide in the adrenals, by 42%±13% (p=0.0008),
whereas the uptake in the pancreas and other organs was
unaffected (Fig. 5). The uptake of
111In-minigastrin and
111In-exendin in organs other than the kidneys was not
affected by peptide #6 and no adverse effects of its injection
were noted.
Fig. 2 Inhibition of the uptake of
111In-albumin (a),
111In-minigastrin
(b)o r
111In-exendin (c) in BN16 cells by intact BSA (10 mg), Gelo
(5 mg) or 100µg of albumin-derived peptides. Results are presented as
mean % bound activity; error bars indicate SEM. *P<0.05;**P<0.005
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Radiation-induced chronic renal damage due to proximal
tubular reabsorption and retention of radiolabelled peptides
limits the activity dose that can safely be administered in
PRRT, thereby limiting the efficacy of this anti-tumour
therapy. The renal reabsorption of
111In-octreotide is, at
least in part, mediated by megalin [9]. Megalin is a
multiligand scavenger receptor that is involved in the renal
reuptake of various peptides and proteins, among which
albumin [12, 13]. We previously reported that both the
protein-based plasma expander Gelo and trypsinised albu-
min are effective inhibitors of the renal reabsorption of
various radiolabelled peptides [1, 21, 22]. In the current
study, we aimed to identify albumin-derived peptides that
are effective inhibitors of the renal uptake of
111In-labelled
minigastrin, exendin and octreotide.
FRALB-C, bovine serum albumin fragmented by cyan-
ogen bromide, proved to be an effective inhibitor of the
uptake of
111In-labelled albumin, minigastrin, exendin and
octreotide in megalin-expressing cells. In rats, FRALB-C
inhibited the renal reabsorption of
111In-octreotide as
efficiently as Gelo. The inhibitory effect of FRALB-C
was comparable to the effects we previously obtained with
trypsinised albumin [1].
FRALB-C is a mixture of at most 28 different albumin
fragments. We expected these different fragments to have
different affinities for megalin. Therefore, we aimed to
further identify specific albumin fragments that inhibited
the renal reuptake of radiolabelled peptides efficiently.
However, attempts to further purify the FRALB-C mixture
by filtration, dialysis and HPLC did not yield sufficiently
purified peptides.
Six albumin-derived peptides were screened for their
ability to reduce the uptake of
111In-albumin,
111In-exendin
and
111In-minigastrin in cells expressing megalin and
cubilin. The uptake of
111In-albumin was inhibited by
peptides #1, #3, #5 and most potently by #6, whereas
peptides # 2 and #4 did not have a significant effect. This
suggests that the amino acid sequences of peptides #1, #3,
#5 and #6 may be involved in the physiological binding of
albumin to its renal receptors. However, since megalin’s
binding domains facilitate the binding of various endoge-
nous and exogenous peptides, it is also possible that some
or all of these sequences are not actually involved in the
binding of intact albumin to megalin; for example because
they may not be exposed at the surface of the albumin
molecule. Each of the peptides #1, #3, #5 and #6 contained
both positively and negatively charged amino acid residues,
whereas peptides #2 and #4 contained only positive or only
negative charges, respectively. It was suggested previously
that the distribution of charges rather than the overall
charge may be important for ligand binding to megalin
Fig. 3 Kidney activity concentrations 20 h after i.v. injection of
111In-
octreotide in rats. One to three minutes prior to the injection of
111In-
octreotide, groups of five rats received 0.5 ml of either PBS, lysine
(80 mg), Gelo (20 mg) or FRALB-C (1 mg). Results are presented as
mean %ID/g, error bars indicate SEM. *P<0.05; **P<0.005
Fig. 4 Kidney activity concentrations 20 h after i.v. injection of
111In-
minigastrin (a),
111In-exendin (b)o r
111In-octreotide (c) in rats. One to
three minutes prior to the injection of the
111In-labelled peptide,
groups of five rats received 0.5 ml of either PBS, Gelo (20 mg) or
albumin-derived peptide #6. Results are presented as mean %ID/g,
error bars indicate SEM. *P<0.05; **P<0.005
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charges might contribute to the binding of albumin to
megalin and / or cubilin.
Exendin contains four positively charged and six
negatively charged amino acid residues, minigastrin con-
tains seven negatively charged amino acid residues and
octreotide contains one positively charged amino acid
residue. Similarly to
111In-albumin, the uptake of
111In-
exendin by BN16 cells was reduced significantly by
peptides #3, #5 and most potently by #6, suggesting that
the binding mechanism of
111In-exendin might be similar to
that of
111In-albumin. In addition to peptides #3, #5 and #6,
peptide #4 significantly reduced the uptake of the exclu-
sively negatively charged
111In-minigastrin as well. Each of
the peptides #3–6 contained at least four negatively charged
amino acid residues, whereas the peptides that did not
reduce the binding of
111In-minigastrin contained three
(peptide #1) and 0 (peptide #2) negative charges. This again
suggests involvement of minigastrin’s multiple negative
charges in its renal reuptake. It has been shown previously
that the effect of polyglutamic acid chains on the renal
reuptake of minigastrin depends on the number of nega-
tively charged residues in these chains [31].
Peptide #6, the larger peptide, inhibited the uptake of
111In-albumin,
111In-exendin and
111In-minigastrin most
effectively in vitro, although it was tested at a lower molar
concentration than the other peptides. Whether its size, its
charge distribution or other properties determine its
effectiveness remains to be investigated. This peptide was
subsequently studied in vivo.
In rats, peptide #6 reduced the renal uptake of
111In-
minigastrin very effectively. The effect of 5 mg of peptide #6
was larger than the effect of 20 mg Gelo. The inhibition of
the renal uptake of
111In-exendin by peptide #6 was less
pronounced, although its effects on the cell binding of
111In-minigastrin and
111In-exendin were comparable in
vitro. A possible explanation for the observed difference is
a relatively short plasma half life of peptide #6. Literature
suggests longer plasma half lives for exendin than for
minigastrin [23, 33]. Peptide #6 might be largely excreted,
while exendin is still present in relatively high concen-
trations in the plasma and the ultrafiltrate. In our previous
study [1], trypsinised albumin had more effect on the renal
uptake of
111In-exendin than peptide #6 had in this study,
which might be explained by a longer half life of this
mixture of peptides. Alternative possible explanations for
the observed differences between
111In-exendin and
111In-
minigastrin in vitro and in vivo include different mecha-
nisms of renal reabsorption (e.g. involvement of different
transporters or receptors), a higher affinity of exendin for
renal receptors, or general differences in transport mech-
anisms and kinetics between the kidneys in vivo and the in
vitro model.
The inhibition of the renal reabsorption of
111In-exendin
and
111In-octreotide by 5 mg of peptide #6 in rats was
comparable to the effects of 20 mg Gelo. The effect of
FRALB-C on the renal uptake of
111In-octreotide was in the
same range. Most other studies using competitive blockers
to reduce the renal retention of
111In-octreotide report
maximum reductions of around 50% [1, 15, 20–22]. The
residual uptake may indicate a contribution of other
mechanisms of renal reuptake, such as fluid phase
endocytosis [34].
Remarkably, peptide #6 significantly reduced the uptake
of
111In-octreotide in the adrenals. Since rat adrenals
predominantly express somatostatin receptor subtype 2
(sstr2) [35] and
111In-octreotide has the highest affinity for
sstr2 and lower affinities for sstr3 and sstr5 [36], this
possibly indicates interference of peptide #6 with the
binding of octreotide to sstr2. However, uptake in other
organs known to express relatively high levels of sstr2,
such as the pancreas and the stomach [37–39], was
unaffected. Other mechanisms for the reduced uptake of
111In-octreotide in the adrenals have to be considered and
future experiments will have to investigate if specific
tumour uptake is affected by peptide #6. Although the
peptide is derived from albumin and we did not observe
any side-effects in the animal experiments, it is a new
substance which may cause toxicity at higher doses.
Therefore, the dose of this peptide that can be administered
safely has to be determined before clinical use becomes
possible.
In summary, peptide #6 is a promising candidate for
inhibition of the renal reabsorption of
111In-minigastrin and
perhaps of
111In-exendin. To reduce the renal reabsorption
Fig. 5 Biodistribution of
111In-octreotide in rats, 20 h post-injection.
One to three minutes prior to the injection of
111In-octreotide, groups
of five rats received 0.5 ml of PBS or peptide #6 (5 mg). Results are
presented as mean %ID/g; error bars indicate SEM. **P<0.005
232 Eur J Nucl Med Mol Imaging (2010) 37:226–234of radiolabelled peptides more efficiently, a combination of
two or more competitive inhibitors of endocytosis and other
approaches may prove to be useful.
Conclusion
Albumin digested by CNBr (FRALB-C) efficiently reduced
the uptake of
111In-labelled albumin, octreotide, minigastrin
and exendin in megalin expressing cells, and reduced the
renal retention of
111In-octreotide in rats. In vitro, the effect
of albumin-derived peptide #6 on the uptake of
111In-exendin
and
111In-minigastrin was comparable to the effect of
FRALB-C and Gelofusine. In rats, peptide #6 efficiently
reduced the renal retention of
111In-labelled octreotide,
exendin and especially minigastrin, opening up new possibil-
ities for the reduction of kidney damage in peptide receptor
radionuclide therapy with less chance of side-effects.
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